Genenta Science S.p.A. has announced ongoing developments in its clinical studies targeting glioblastoma multiforme and genitourinary tumors. In the glioblastoma multiforme (TEM-GBM) study, 38 patients have been enrolled, with 25 receiving the investigational treatment, Temferon. Notably, two patients in the long-term follow-up study have survived three years post-surgery, with observations suggesting potential Temferon-mediated control of disease progression. These findings may require further investigation in larger trials. Simultaneously, Genenta has initiated the TEM-GU Phase 1 study, which aims to enroll 12 patients with genitourinary tumors. This study seeks to evaluate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma, using a fixed dose of genetically modified cells. The trial will also explore Temferon's potential synergy with immune checkpoint inhibitors or tyrosine kinase inhibitors. Results of this study will be presented in the future, once sufficient data is collected to allow for meaningful analysis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genenta Science S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001115751-en) on July 01, 2025, and is solely responsible for the information contained therein.
Comments